ArticlePDF Available

The effect of mastic gum on Helicobacter pylori: A randomized pilot study

Authors:

Abstract

Our aim was to study the effect of pure mastic gum on Helicobacter pylori (H. pylori) eradication in patients suffering from an H. pylori infection Fifty two patients were randomized to receive either 350mg three times a day (tid) of pure mastic gum for 14 days (Group A), or 1,05g tid of pure mastic gum (Group B) for 14 days, or pantoprazole 20mg twice a day (bd) plus pure mastic gum 350mg tid for 14 days (Group C) or pantoprazole 20mg bd plus amoxicillin 1g bd plus clarithromycin 500mg bd for 10 days (Group D). All patients harboured H. pylori before entering the study and that was confirmed by a (13)C urea breath test (UBT). H. pylori eradication was tested by a UBT 5 weeks after completion of the eradication regime. Eradication of H. pylori was confirmed in 4/13 patients in Group A and in 5/13 in Grour B. No patient in Group C achieved eradication whereas 10/13 patients in Group D had a negative UBT. There were no statistically significant differences in mean UBT values in Groups A, B, C although there was a trend in Group A (p=0.08) and in Group B (p=0.064). The difference was significant in Group D (p=0.01). All patients tolerated mastic gum well and no serious adverse events were reported. Mastic gum has bactericidal activity on H. pylori in vivo.
Short Communication
The effect of mastic gum on Helicobacter pylori: A randomized pilot study
K.J. Dabos
, E. Sfika, L.J. Vlatta, G. Giannikopoulos
Department of Gastroenterology, Chios General Hospital Skylitsion, Helenas Venizalou 2, 82100 Chios, Greece
article info
Keywords:
Herbal remedies
Monotherapy
Chios mastiha
abstract
Our aim was to study the effect of pure mastic gum on Helicobacter pylori (H. pylori) eradication in
patients suffering from an H. pylori infection
Fifty two patients were randomized to receive either 350 mg three times a day (tid) of pure mastic
gum for 14 days (Group A), or 1,05 g tid of pure mastic gum (Group B) for 14 days, or pantoprazole 20 mg
twice a day (bd) plus pure mastic gum 350 mg tid for 14 days (Group C) or pantoprazole 20 mg bd plus
amoxicillin 1 g bd plus clarithromycin 500 mg bd for 10 days (Group D). All patients harboured H. pylori
before entering the study and that was confirmed by a
13
C urea breath test (UBT). H. pylori eradication
was tested by a UBT 5 weeks after completion of the eradication regime.
Eradication of H. pylori was confirmed in 4/13 patients in Group A and in 5/13 in Grour B. No patient
in Group C achieved eradication whereas 10/13 patients in Group D had a negative UBT. There were no
statistically significant differences in mean UBT values in Groups A, B, C although there was a trend in
Group A (p= 0.08) and in Group B (p =0.064). The difference was significant in Group D (p= 0.01). All
patients tolerated mastic gum well and no serious adverse events were reported. Mastic gum has
bactericidal activity on H. pylori in vivo.
&2009 Elsevier GmbH. All rights reserved.
Introduction
Helicobacter pylori (H. pylori) is a Gram-negative spiral
bacterium that colonises the stomach. Its prevalence in Europe
is in the range of 10-25% and has been falling during the last
decades while in the developing world it is estimated that its
prevalence is much higher (Magalhaes-Queiroz and Luzza 2006).
Infection with H. pylori is etiologically linked to gastritis, peptic
ulcer disease, primary B cell gastric lymphoma and adenocarci-
noma of the stomach (Lai and Sung 2007;Eslick 2006). H. pylori
can be eradicated but this is difficult to achieve and at least two
antibiotics and an acid suppressant are required to achieve
eradication (Malfetrheiner et al. 2007). Side effects for these
regimes are common and a major concern is the development of
antimicrobial resistance. Development and testing of new safe
alternatives to those regimes is therefore warranted.
Mastic gum is a natural resin that is excreted from the trunk
and branches of the mastic bush (Pistacia Lentiscus var. Chia). This
excretion is produced by incising the bark with a sharp
instrument. Mastic gum appears in the incisions in the form of
tears and exudes in droplets onto the soil. While it is flowing, it is
a gummy, clear liquid; it solidifies in irregular shapes after 15-20
days.
Collection is completed in September. Then it is cleaned first by
hand and then with mechanized means. Finally mastic gum is
sorted, classified and graded according to the color and size of the
granule.
The clean mastic gum granules were milled to fine powder
(particle size o200
m
m) by using a Hosokawa Alpine Fine Impact
Mill 100 UP2 (Hosokawa Alpine, Augsburg, Germany). The
encapsulation of powder was performed using the Profill Capsule
Filling System (Torpac Inc, Mumbai, India). Capsule shells
(Capsulegel, V caps, size 0) were made of Hypromellose (Hydro-
xypropyl methylcellulose) and each contained 0.35 (70,002) g of
mastic powder.
There have been references to mastic gum as a medicinal
product since ancient times. It has successfully been used in
gastrointestinal upsets (Kaliora et al. 2007).
Previous studies have shown some effect of mastic gum on the
healing of peptic ulcers in humans (Al-Habbal et al. 1984;Al Said
et al. 1986). Those studies were conducted before the discovery of
H. pylori. A recent case study has shown no effect of mastic gum
on H. pylori (Bebb et al. 2003).
The aim of our randomised controlled trial was to assess the
efficacy of mastic gum monotherapy or in combination with a
proton pump inhibitor on H. pylori eradication and to compare this
efficacy with the standard treatment regime.
Patients and methods
This prospective randomized controlled trial study was con-
ducted at the Gastroenterology Department of Chios General
ARTICLE IN PRESS
Contents lists available at ScienceDirect
journal homepage: www.elsevier.de/phymed
Phytomedicine
0944-7113/$ - see front matter &2009 Elsevier GmbH. All rights reserved.
doi:10.1016/j.phymed.2009.09.010
Corresponding author. Tel.: +302651080738; fax: + 302651080642.
E-mail address: kostasophia@yahoo.com (K.J. Dabos).
Phytomedicine 17 (2010) 296–299
ARTICLE IN PRESS
Hospital Skylitsion. The study was approved by the Local Ethics
Committee and the Greek Medicines Agency.
All eligible patients had an upper gastrointestinal endoscopy
and were found to harbour H. pylori by a rapid urease test (CLO
test, Kimberky Clark, Draper, Utah, USA).They were then asked to
participate in the study and gave their written informed consent.
Patients were excluded if they had a gastric or duodenal ulcer,
were pregnant women or had used in the previous 4 weeks, non
steroidal anti-inflammatory drugs, anticoagulants, steroids, pro-
ton pump inhibitors or antibiotics. Patients who chewed mastic
gum more than once a week were also excluded from the study.
Patients had confirmation of their H. pylori infection by a
13
C
urea breath test (UBT) (INFAI, York, UK). They were then
randomized to receive either a low dose mastic gum monotherapy
350 mg three times a day (tid) for 14 days, a high dose mastic gum
monotherapy 1g tid for 14 days, a dual regime of mastic gum
350 mg tid and pantoprazole 20 mg bd for 14 days, or a standard
triple therapy which consisted of pantoprazole 20 mg bd,
amoxicillin 1 g bd and clarithromycin 500 mg bd for 10 days.
They were asked to keep a log of adverse events. One week into
the study patients received a telephone call, in which their
compliance was assessed and an enquiry on possible adverse
events was made. At the end of the study a physical examination
was performed as well as routine laboratory tests.
Five weeks after the end of treatment, eradication was tested
with a second UBT.
Pure mastic gum was dispensed in capsule form. It contained
no additives or flavourings that could have an effect on its activity.
The randomization was generated using Proc random (SAS
version 6.9). The randomization code was kept at the Central
Pharmacy of Chios General Hopsital Skylitsion. The technician
who performed the UBTs and the operator who analysed the UBTs
were blinded as to which treatment each patient had received.
Data record and statistical analysis
Data were recorded prospectively in case report forms for all
participating patients. All analysis was conducted by intention to
treat. Results are shown as mean and SEM.
Comparisons between UBT values before and after the
intervention were made using the paired t-test. A pvalue of
o0.05 was taken as significant (two-tail test of significance).
Results and discussion
We enrolled fifty two patients from the Endoscopy unit: 13
received low mastic gum monotherapy 350mg tid for 14 days
(Group A), 13 received high mastic gum monotherapy 1g tid for 14
days (Group B), 13 received mastic gum 350 mg tid and
pantoprazole 20 mg bd for 14 days (Group C) and 13 patients
received triple therapy with pantoprazole 20mg bd, amoxicillin
1 g bd and clarithromycin 500 mg bd for 10 days (Group D).
There were no statistically significant differences between
groups with regards to age, sex, previous use of antibiotics or
proton pump inhibitors.
One patient from Group A completed the study but did not
return for his follow up UBT 5 weeks later. Two patients from
Group C completed the study but did not return for their UBT 5
weeks later. One patient in Group D stopped because of side
effects (diarrhoea and abdominal cramps).
Table 1 shows an overview of the results. Four patients in
group A achieved eradication (30,8%), whereas five in Group B
(38,5%) none in Group C and ten patients in Group D (76,92%)
achieved eradication.
UBT was performed a mean of 8 days (4-14 days) before
starting treatment. It was repeated a mean of 39 days (33-61 days)
after completion of the study medication. Fig. 1 shows mean UBT
values before and after treatment. There was a trend towards
significance in Group A (28.8674.4 vs 18.7673.1) (p= 0.08), and
in Group B (27.1175.2 vs 17.6874.8)(p =0.064). Group C showed
no difference (25.5673.8 vs 23.67 74.7) (p =NS) There was a
statistically significant difference in UBT values in Group D
(26.7373.9 vs 7.8572.8) (p o0.01).In nine patients in Group A
and ten patients in Group B the UBT value post treatment
decreased compared with the UBT value before treatment.
Patients who received mastic gum tolerated it well. One
patient in Group A complained of diarrhoea and another in Group
B complained of nausea. Both completed the therapy as per
protocol. Three patients in Group D complained of abdominal
cramping and diarrhoea, one stopped the treatment on day 4.
This study was designed to evaluate the effect of Mastic gum
on H. pylori in vivo. Our results showed that mastic gum has some
effect on H. pylori in vivo. Nine patients in the monotherapy groups
achieved eradication while in ten more patients the UBT value
decreased compared to the pre-treatment reading. UBT values
have been shown to provide rather accurate estimation of the in
vivo H. pylori load (Perri et al. 1998).
We have also shown that the combination of mastic gum and
pantoprazole was ineffective in eradicating H. pylori but it had no
effect on bacterial load either. Our control group with standard
triple therapy achieved an acceptable eradication rate.
The constituents which might contribute to the therapeutic
effects of mastic gum belong to the class of mono- and
sesquiterpenoids (essential oils) (Barra et al. 2007) and triterpe-
noids (e.g. masticadienonic acid) (Assimopoulou and Papageor-
giou 2005). Previous in vitro studies have shown that crude mastic
gum possesses antibacterial properties against H. pylori (Huwez et
al. 1998;Marone et al. 2001). A recent study has shown that the
acid fraction of mastic gum which contains triterpenic acids and
constitutes about 50% of its total weight has bactrericidal activity
against H. pylori (Paraschos et al. 2007). In particular, moronic acid
seems to be a powerful antibiotic not only against H. pylori but
also other bacteria (Hostettmann-Kaldas and Nakanishi 1979).
The activity of mastic gum against H. pylori in vivo was the
subject of studies with conflicting results. Early studies showed
bactericidal activity on H. pylori in vitro and it was hypothesized
that mastic gum killed H. pylori and thus helped ulcer healing
(Huwez et al. 1998;Marone et al. 2001). Unfortunately, two recent
in vivo studies, one in mice and the other in humans showed no
eradication of H. pylori and only a modest antibacterial activity
(Bebb et al. 2003;Loughlin et al. 2003).
Mastic gum is a herbal remedy and all studies that used mastic
gum on patients showed minimal side effects (Al-Habbal et al.
1984;Al Said et al. 1986;Bebb et al. 2003). Also a recent study on
animals showed that long term use of mastic gum was not
Table 1
Patients in Group A received low dose mastic gum monotherapy for 14 days. Group
B patients received high dose mastic gum monotherapy for 14 days. Group C
patients received mastic gum and pantoprazole for 14 days. Group D received
triple therapy with pantoprazole, amoxicillin and clarithromycin for 10 days.
Results are shown as mean7SEM
Eradication UBT pre UBT post p
Group A 4/13 (30.8%) 28.8674.4 18,76 73.1 0.08
Group B 5/13(38.5%) 27.11 75.2 17.6874.8 0.064
Group C 0/13 25.56 73.8 23.6774.7 NS
Group D 10/13 (76,92%) 26.7373.9 7.8572.8 0.01
Abbreviations: UBT= Urea breath test values.
K.J. Dabos et al. / Phytomedicine 17 (2010) 296–299 297
ARTICLE IN PRESS
associated with serious side effects (Kang et al. 2007). As a
considerable fraction of patients harbouring the bacterium are
unable to tolerate triple therapy due to side effects mastic gum
might provide a reasonable alternative in the future.
The fact that the combination of mastic gum and pantoprazole
showed no effect on H. pylori is somewhat surprising. Most active
substances of mastic gum belong to its acidic fraction. They
possibly require an acidic environment in the stomach to
successfully kill H. pylori. Proton pump inhibitors block the
hydrogen potassium ATP enzyme system on the gastric parietal
cells. In that way, they increase the intragastric pH. Buffering the
acidity of the stomach by the proton pump inhibitors could result
in a hostile environment for mastic gum. This hypothesis needs to
be tested in further studies.
We have used two doses of mastic gum in our study the main
reason being that a low dose mastic gum monotherapy has shown
some activity in a previous study (Al-Habbal et al. 1984) while a
high dose monotherapy has been shown to be ineffective in
another study (Bebb et al. 2003).
Our study has limitations, the main one being its small size. We
also did not use two different methods of confirming H. pylori status
after treatment as a second endoscopy was deemed inappropriate.
In conclusion, this proof of principle study showed that mastic
gum possesses antibacterial activity against H. pylori in vivo and is
able to eradicate it from patients. Although even the high dose
monotherapy did not achieve acceptable eradication rates it could
be used as an alternative regime in patients unwilling to undergo
eradication with the triple therapy regime.
Acknowledgements
The study was funded by the Chios Mastic Gum Growers
Association
Konstantinos John Dabos declares that he received a travel
bursary from the sponsor during the study period.
Ekaterini Sfika was an employee of the sponsor during the
study period
Lisa Jo Vlatta and Georgios Giannikopoulos have nothing to declare
The study is registered with Controlled Trials and its registra-
tion number is ISRCTN01756929 The URL of the trial register is
www.controlled-trials.com
References
Al-Habbal, M.J., Al-Habbal, Z., Huwez, F.U., 1984. A double blind controlled clinical
trial of mastic and placebo in the treatment of duodenal ulcer. Clin. Exp.
Pharmacol. Physiol. 11, 541–544.
Al Said, M., Ageel, A.M., Parmar, M.S., Tariq, M., 1986. Evaluation of mastic a crude
drug obtained from Pistacia lentiscus for gastric and duodenal anti-ulcer
activity. J. Ethnopharmacol. 15, 271–278.
Assimopoulou, A.N., Papageorgiou, V.P., 2005. GC-MS analysis of penta- and
tetracyclic-triterpenes from resin of Pistacia species. Part II. Pistacia terebiuthus
var. Chia. Biomed. Chromatogr. 19 (8), 586–605.
Barra, A., Coroneo, V., Dessi, S., Cabros, P., Angioni, A., 2007. Characterization of the
volatile constituents in the essential oil of Pistacia lentiscus L. from different
origins and its antifungal and antioxidant activity. J. Agric. Food Chem. 55 (17),
7093–7098.
Bebb, J.R., Bailey-Flitter, N., Ala’Aldeen, D., Atherton, J.C., 2003. Mastic gum has
no effect on Helicobacter pylori load in vivo. J. Antimicrob. Chemother. 52,
522–523.
Eslick, J.D., 2006. Helicobacter pylori infection causes gastric cancer? A review of
the epidemiological, meta-analytic and experimental evidence. World J.
Gastroenterol. 12, 2991–2999.
Hostettmann-Kaldas, M., Nakanishi, M., 1979. Moronic acid a simple triterpenoid
keto- acid with antimicrobial activity isolated from Ozorooa mucronata. Planta
Med. 37, 358–360.
Huwez, F.U., Thorwell, D., Cockayne, A., Ala’Aldeen, D.A., 1998. Mastic gum kills
helicobacter pylori. N. Engl. J. Med. 346, 1946.
Kaliora, A.C., Stathopoulou, M.G., Triantafillidis, J.K., Dedoussis, G.V., Andikopoulos,
N.K., 2007. Chios mastic treatment of patients with active Crohn’s disease.
World J. Gastroenterol. 13, 748–753.
Kang, J.S., Wanibuchi, H., Salim, E.I., Kinoshita, A., Fukushima, S., 2007. Evaluation
of the toxicity of mastic gum with 13 weeks dietary administration to F344
rats. Food Chem. Toxicol. 45, 494–501.
Lai, L.H., Sung, J.J., 2007. Helicobacter pylori and benign upper digestive diseases.
Best Pract. Res. Clin. Gastroenterol. 21, 261–279.
Loughlin, M.F., Ala’Aldeen, D.A., Jenks, P.J., 2003. Monotherapy with mastic gum
does not eradicate Helicobacter pylori infection from mice. J. Antimicrob.
Chemother. 51, 367–371.
UBT test values in the four groups
0
5
10
15
20
25
30
35
Before treatment
After treatment
Group A Group B Group C Group D
Fig. 1. Urea breath test (UBT) was reformed a mean of 8 days (4-14 days) before starting treatment. It was repeated a mean of 39 days (33-61 days) after completion of the
study medication. Mean values of UBT before and after treatment are shown There was a trend towards significance in Group A (28.8674.4 vs 18.7673.1) (p= 0.08), and in
Group B (27.1175.2 vs 17.6874.8) (p =0.064). Group C showed no difference (25.56 73.8 vs 23.6774.7) (p =NS) There was a statistically significant difference in UBT
values in Group D (26.7373.9 vs 7.8572.8) (p o0.01).
K.J. Dabos et al. / Phytomedicine 17 (2010) 296–299298
ARTICLE IN PRESS
Magalhaes-Queiroz, D.M., Luzza, F., 2006. Epidemiology of Helicobacter pylori
infection. Helicobacter 11 (Suppl.1), 1–5.
Malfetrheiner, P., Megraud, F., O’Morain, C., Bazzoli, F., El-Omar, E., Graham, D., et
al., 2007. Current concepts in the management of Helicobacter pylori infection:
the Masstricht III consensus report. Gut 56, 772–781.
Marone, P., Bono, L., Leone, F., Bona, S., Carretto, E., Perversi, L., 2001. Bactericidal
activity of Pistacia lentiscus mastic gum against Helicobacter pylori. J. Che-
mother. 13, 611–614.
Paraschos, S., Magiatis, P., Mitakou, S., Petraki, K., Kalliaropoulos, A., Maragkou-
dakis, P., et al., 2007. In vitro and in vivo activities of Chios mastic gum extracts
and constituents against Helicobacter pylori. Antimicrob. Agents Chemother. 51,
551–559.
Perri, F., Clemente, R., Pastore, M., Quitadamo, M., Festa, V., Bisceglie, M., et al.,
1998. The C
13
urea breath test as a predictor of intragastric bacterial load
and severity of Helicobacter pylori gastritis. Scand J. Clin. Lab. Invest. 58,
19–27.
K.J. Dabos et al. / Phytomedicine 17 (2010) 296–299 299
... The oxidized fractions of mastic gum fractions showed 99% mortality of H. pylori (Sharif et al., 2009). When compared to high dose of mastic gum, a low dose effectively eradicated the H. pylori (Dabos et al., 2010). Similarly, Taha and Eldahshan (2017) concluded the antimicrobial activity of C. glanduliferum essential oil against H. pylori, yet toxicity and side effects need to be carried by LD 50 . ...
... Hence, they increase intragastric pH by inhibiting H + /K + ATP enzyme system on parietal cells of gastric mucosa. This method can be used in patients unwilling to take triple therapy (Dabos et al., 2010). Sclerocarya birrea stem bark contains terpinen-4-ol which exhibits antimicrobial activity, is attributed to its hydrophilic/hydrophobic nature, plus easy diffusion through bacterial cell wall by increasing its permeability to cytoplasmic membrane fluidity. ...
... Observations have revealed that MG has gastro-protective possessions 4 and is effective against H. pylori 5 and helps in its eradication therapy. The aim of implementing the MMS of ATH (AMMM) is to achieve stable systemic availability over a longer period. ...
... The authors employed MG (mastic gum) in the study of mucoadhesive microspheres. MG has been shown to have a healing effect on stomach/peptic ulcers and is effective against H. pylori which is devoid of side effects [6,7]. Systemic availability at a steady state is the aim of AMMM. ...
... Researchers studied mucoadhesive microspheres with MG (Mastic gum). MG has been revealed to have a healing effect on stomach/peptic ulcers and is effective against H. pylori [11][12][13]. The work aiming at ATH mastic gum mucoadhesive microspheres (AMMM) is to reach a steady-state systemic availability in expanded time. ...
... Dabos et al. (20) designed a study in which participants were randomly divided into four arms to intake 350 mg of pure mastic gum three times a day (A), 1.05 g of pure mastic gum three times a day (B), 20 mg of pantoprazole twice a day plus 350 mg of pure mastic gum three times a day (C), or a triple therapy consisting of pantoprazole, amoxicillin, and clarithromycin (D). For all the patients, confirmation of H. pylori was performed using UBT. ...
Article
Full-text available
: Antibiotic-resistant Helicobacter pylori isolates have become a global concern. The standard triple or quadruple therapies have recently become the most effective protocol for eradicating H. pylori in the gastrointestinal tract. There is evidence regarding the impact of different complementary or dietary supplements on H. pylori eradication. This review article intended to search electronic bibliographic databases for any clinical studies that evaluated the use of any herbal or dietary supplements to eradicate H. pylori up to June 2021. A total of 20 human studies met our criteria and were reviewed. Although some herbal medicines have shown their efficacy and safety in eradicating H. pylori in different clinical trials, more randomized blind, placebo-controlled human trials with a large sample size must be performed to extend our knowledge.
... The gum resins contain triterpenes (constituting 65-70%) comprising tetracyclic and pentacyclic triterpenes which are derivatives of tirucallane, dammarane, oleanane, and lupane skeletons [9], essential oil containing the major components α-pinene and β-myrcene [10], and a range of dicyclic triterpenes (1-2% of the total resin) [11]. Multiple lines of evidence suggest that Pistacia resins can inhibit the production of both NO and PGE 2 in lipopolysaccharide (LPS)-activated RAW264.7 cells [12], decrease the IL-6, and C-reactive protein (CRP) plasma levels [13], and limit an increase in plasma free amino acids for maintenance and recovery of intestinal functions [14]. ...
Article
Full-text available
Pistacia lentiscus L. is an evergreen shrub belonging to the Anacardiaceae family, cultivated exclusively in the southern area of Chios Island. Mastic gum as a unique natural resin of the tree Pistacia lentiscus L. has been used extensively in functional foods and traditional medicine. The biological properties of Pistacia resins may be influenced by different chemical constituents. Herein the present work is aimed to further explore the diverse triterpenoids of mastic, and evaluate their anti-inflammatory activity. Two undescribed polypodane-type bicyclic triterpenoids were isolated from the Pistacia resins, their structures were elucidated using ultraviolet, infrared, high resolution electrospray ionization mass spectroscopy (HRESIMS), and nuclear magnetic resonance data. LPS-stimulated RAW264.7 macrophages were incubated with various concentrations of isolated compounds, and results showed that compounds 1 and 2 inhibited nitric oxide production in LPS-induced RAW264.7 cells with IC 50 values of 28.1 and 32.6 µM, respectively.
Article
Introduction: Chios Mastiha essential oil (CMO) is a natural product extracted from the resin of Mastiha, possessing antioxidant, anti-microbial, anti-ulcer, anti-neoplasmatic and cholesterol lowering capabilities in vitro, and its hypolipidemic effect was confirmed in animal studies. Yet, there are no randomized, placebo-controlled clinical studies in the literature regarding CMO's hypolipidemic effects in humans. A prospective, randomized, placebo-controlled study was designed to study the hypolipidemic effect of CMO capsules on healthy volunteers with elevated cholesterol. Methods: 192 healthy volunteers were screened and 160 of them with total cholesterol> 200 mg/dl participated in the study. They were randomized with a 2:1 ratio of receiving CMO capsules (200 mg mastiha-oil/capsule) and placebo for 8 weeks respectively. 113 patients received CMO and 47 were randomized in the control group, and all of them completed the follow-up period. Results: After 8 weeks of CMO administration, total and LDL cholesterol were significantly lower in the CMO compared to the placebo group 215.2±27.5 vs 237.0±27.9 mg/dl (p<0.001) and 135.0±26.1 vs 153.0±23.3 mg/dl (p<0.001) respectively. No gastrointestinal adverse events, liver or renal toxicity were reported. Additionally, in the CMO group total cholesterol was significantly decreased by 20.6 mg/dl (9%) and LDL by 18.1 mg/dl (12%), triglycerides by 21.8 mg/dl (15%) and glucose by 4.6 mg/dl (5%) and HDL was increased by 2.4 mg/dl (5%), compared to their baseline values. Conclusion: MASTIHA-OIL study showed the efficacy and safety of CMO in reduction of Total and LDL-cholesterol after 8 weeks of administration in healthy volunteers with elevated cholesterol levels.
Article
Full-text available
Between 2018 and 2021, several mastic trees (Pistacia lentiscus var. Chia) sampled in the field and the nursery of the Chios Mastiha Growers Association (CMGA) were analyzed to determine the cause of dominant diseases. Symptoms included defoliation, leaf, and twig blight, wilting and/or apoplexy of trees and apoplexy of young hardwood cuttings. Moreover, brown discoloration had also been observed on older woody parts of the trees such as branches and tree trunks. Several pathogens have been isolated and identified as the causing agents. Neopestalotiopsis and Alternaria species were isolated consistently from necrotic tissues of mastic trees (branches, twigs, and leaves) in the field and the nursery. All fungal isolates’ pathogenicity was confirmed by applying Koch’s postulates on young mastic trees under glasshouse conditions. Fungal pathogens were identified by sequence analyses of the ITS, β-tubulin, and histone gene regions. Alternaria species were analyzed further by sequencing the endopolygalacturonase (endoPG) and the Alternaria major allergen (Alta1) genes. More specifically, the isolates were identified as Neopestalotiopsis clavispora, Alternaria arborescens, and A. alternata based on morphological features and sequence analyses. This is the first report of N. clavispora, A. arborescens, and A. alternata on P. lentiscus var. Chia.
Article
Full-text available
To the Editor: Even low doses of mastic gum — 1 mg per day for two weeks — can cure peptic ulcers very rapidly, but the mechanism responsible has not been clear. We have found that mastic is active against Helicobacter pylori, which could explain its therapeutic effect in patients with peptic ulcers. Mastic is a resinous exudate obtained from the stem and the main leaves of Pistacia lentiscus. It is used as a food ingredient in the Mediterranean region. Clinically, mastic has been effective in the treatment of benign gastric ulcers1 and duodenal ulcers.2 In rats, mastic showed cytoprotective . . .
Article
Full-text available
To determine the ability of mastic monotherapy to eradicate Helicobacter pylori infection from mice. The susceptibility of H. pylori SS1 to mastic was assessed by broth dilution determination of the MIC and MBC. Mice were inoculated intragastrically with either a suspension of H. pylori SS1 (n = 70) or brain-heart infusion broth alone (n = 10). Mice were given antimicrobial chemotherapy 4 weeks after infection and were administered the mouse equivalent of either 2 g of mastic twice daily for 7 days or a triple therapy regimen containing the mouse equivalent of 400 mg of metronidazole, 250 mg of clarithromycin and 20 mg of omeprazole twice daily for 7 days. Mice were killed either immediately or 1 month after the completion of treatment, and their stomachs cultured for H. pylori. The mastic MIC and MBC of H. pylori SS1 were 7.80 and 31.25 mg/L, respectively. The triple therapy regimen eradicated infection from 19 of 20 SS1-infected mice. Mastic failed to eradicate infection from any of the 18 SS1-infected mice (P < 0.001) and there was no signifi- cant reduction in gastric bacterial load in mice treated with this regimen. Despite reported beneficial effects in ulcer patients and the good in vitro activity of mastic against H. pylori, this compound is unable to eradicate H. pylori infection from mice.
Article
SUMMARY1. A double-blind clinical trial was carried out on thirty-eight patients with symptomatic and endoscopically proven duodenal ulcer to compare the therapeutic responses to mastic (1 g daily, twenty patients) and placebo (lactose, 1 g daily, eighteen patients) given orally over a period of 2 weeks.2. Symptomatic relief was obtained in sixteen (80%) patients on mastic and in nine (50%) patients on placebo, while endoscopically proven healing occurred in fourteen (70%) patients on mastic and four (22%) patients on placebo. The differences between treatments were highly significant (P<0.01). Mastic was well tolerated and did not produce side effects.3. It is concluded that mastic has an ulcer healing effect, but further studies are needed to establish its role in treating peptic ulcer.
Article
Root bark extract of the East African medicinal plant Ozoroa mucronata showed antimicrobial activity against Gram–positive bacteria. Fractionation of the extract following the results of bioassay led to isolation of the active factor C30H46O3. Spectroscopic studies indicated the olean–18–ene keto acid structure 1 („moronic acid”), isolated for the first time in nature. The relatively simple structure of this bioactive triterpene is noted.
Article
The effect of mastic, a concrete resinous exudate obtained from the stem of the tree Pistacia lentiscus, has been studied on experimentally-induced gastric and duodenal ulcers in rats. Mastic at an oral dose of 500 mg/kg produced a significant reduction in the intensity of gastric mucosal damage induced by pyloric ligation, aspirin, phenylbutazone, reserpine and restraint + cold stress. It produced a significant decrease of free acidity in 6-h pylorus-ligated rats and a marked cytoprotective effect against 50% ethanol in rats which could be reversed by prior treatment with indomethacin. The protective effect was not seen when it was given intraperitoneally in phenylbutazone and restraint + cold stress models. The reduction in the intensity of ulceration in cysteamine-induced duodenal ulcers was not found to be statistically significant in mastic-pretreated rats. The results suggest that mild antisecretory and a localized adaptive cytoprotectant action may be responsible for its anti-ulcer activity. These observations support the results of an earlier study on the clinical effectiveness of mastic in the therapy of duodenal ulcer.
Article
The urea breath test (UBT) has been proposed as the most accurate test for diagnosing Helicobacter pylori infection. The aim of this work was to evaluate the accuracy of the UBT and to compare the results with histologic and endoscopic findings in H. pylori infected patients. One-hundred-and-seventy-two consecutive dyspeptic outpatients were studied by means of endoscopy (with histology and culture), UBT (75 mg 13C-urea), and serology. Gastritis was classified in accordance with the Sydney criteria. In H. pylori positive patients, the bacterial load was assessed semiquantitatively, the number of bacteria in histologic specimens being counted. UBT results were expressed either as percentage cumulative dose of 13CO2 excreted at 1 h (CD60) or delta over baseline at 30' (DOB30). Of 172 patients, 126 (73%) were H. pylori positive on histology or culture. Using a cut-off value of 3.3/1000 for DOB30, the sensitivity, specificity and accuracy of the UBT were 96%, 93.5%, and 95.3%, respectively. A significant correlation was observed between DOB30 values and intragastric bacterial load (r = 0.32). Moreover, a significant difference in DOB30 values was found between patients sorted by the depth of inflammation (chi(2) = 4.36, p = 0.036). No correlation was observed between DOB30 and endoscopic findings in H. pylori positive subjects. The UBT is an accurate non-invasive diagnostic tool and can be used to predict both the intragastric bacterial load and the severity of related gastritis.
Article
In this study we evaluated the antibacterial activity of mastic gum, a resin obtained from the Pistacia lentiscus tree, against clinical isolates of Helicobacter pylori. The minimal bactericidal concentrations (MBCs) were obtained by a microdilution assay. Mastic gum killed 50% of the strains tested at a concentration of 125 microg/ml and 90% at a concentration of 500 microg/ml. The influence of sub-MBCs of mastic gum on the morphologies of H. pylori was evaluated by transmission electron microscopy. The lentiscus resin induced blebbing, morphological abnormalities and cellular fragmentation in H. pylori cells.